Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Researchers at Washington University School of Medicine in St. Louis have conducted a longitudinal study on an individual ...

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...